Redefining patient access strategy

Run time

1 minute, 12 seconds

Patient access continues to be a major hurdle in the US pharma industry, impacting the speed of drug development and therefore the delivery of life-saving treatments to patients. To assess the current state of patient access, Norstella’s Managed Markets Insight & Technology (MMIT) surveyed over 300 industry professionals on major trends and challenges in pharma and how they can be improved upon as the landscape continues to evolve. The following video highlights the survey’s key findings and how industry can use this data to inform their patient access strategy in the future.

Partnering with Norstella provides access to timely data and insights that allows industry players to stay ahead of the curve. If you would like to learn more about partnering with Norstella to optimize your approach to patient access, visit our solutions page.

The full, in-depth MMIT patient access report is also available online today!

Frequently asked questions

What is patient access in the pharmaceutical industry?

Patient access refers to how quickly and effectively patients can obtain prescribed therapies, including overcoming barriers related to coverage, reimbursement, affordability, and payer requirements.

Why is patient access such a major challenge in the US pharma industry?

Patient access challenges are often driven by evolving payer policies, utilization management restrictions, reimbursement complexities, and increasing pressure to demonstrate value and affordability.

How does patient access impact drug development?

Access barriers can delay therapy adoption, limit patient uptake, and influence commercialization success, making patient access strategy a critical part of the drug development lifecycle.

What was the goal of Norstella’s patient access survey?

The survey was designed to better understand the current challenges, trends, and opportunities shaping patient access across the pharmaceutical industry.